Interpretation of the PRISMA extension for Chinese herbal medicine review (PRISMA-CHM)_Chinese Journal of Evidence-Based Medicine

Authors：

LI Yuxin ¹ ,  XIONG Jun ^2,3 , ZHANG Zheng ^2,3 , LIAO Kai ^2,3 , ZHOU Xiaohong ^2,3 , LI Jun ^2,3 , XIANG Jie ^2,3 , XU Lingling ^2,3

1. Graduate School, Jiangxi University of Chinese Medicine, Nanchang 330004, P. R. China;
2. Department of Acupuncture Allergic Rhinitis, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang 330006, P. R. China;
3. Key Laboratory of Evidence-based Evaluation of Chinese Medicine for Health in Jiangxi Province, Nanchang 330006, P. R. China;

Corresponding?author：

XIONG Jun, Email: xiongjun196071@163.com

Keywords：

Chinese herbal medicine; Systematic review; Meta-analysis; PRISMA-CHM; Reporting standard; Interpretation

DOI：

10.7507/1672-2531.202303057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

According to the evidence pyramid model, systematic review (SR)/meta-analysis (MA) is one of the essential sources with a high level of clinical evidence. A high-quality SR/MA can effectively guide clinical decision-making and practice. The preferred reporting items for systematic reviews and meta-analyses extension for Chinese herbal medicines (PRISMA-CHM) were officially published in 2020. In this study, based on research cases, the features of PRISMA-CHM were interpreted in detail, so as to help domestic users accurately grasp the details of the reports, in order to improve the quality of the reports of SR/MA of traditional Chinese medicine.

Citation： LI Yuxin, XIONG Jun, ZHANG Zheng, LIAO Kai, ZHOU Xiaohong, LI Jun, XIANG Jie, XU Lingling. Interpretation of the PRISMA extension for Chinese herbal medicine review (PRISMA-CHM). Chinese Journal of Evidence-Based Medicine, 2023, 23(11): 1351-1359. doi: 10.7507/1672-2531.202303057 Copy

1.	Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312(7023): 71-72.
2.	Lin SS, Liu CX, Zhang JH, et al. Efficacy and safety of oral Chinese patent medicine combined with conventional therapy for heart failure: an overview of systematic reviews. Evid Based Complement Alternat Med, 2020, 2020: 8620186.
3.	Egger M, Davey Smith G, Altman DG, et al. Systematic reviews in health care: meta-analysis in context (2nd editon). London: BMJ Books, 2001.
4.	Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet, 1999, 354(9193): 1896-1900.
5.	Lee AW. Use of network meta-analysis in systematic reviews: a survey of authors. Syst Rev, 2016, 5: 8.
6.	Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 2009, 339: b2700.
7.	衷敬柏, 王階, 王永炎. 方劑的復雜性與中藥新藥開發. 中國中藥雜志, 2002, 27(5): 321-323.
8.	張素珍. 西藥與中成藥的聯系與區別. 幸福家庭, 2020, (17): 118.
9.	劉洋. 近代中醫體制化歷程(1919-1937). 太原: 山西大學, 2017.
10.	Zhang X, Tan R, Lam WC, et al. PRISMA (preferred reporting items for systematic reviews and meta-analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020). Am J Chin Med, 2020, 48(6): 1279-1313.
11.	Yan Y, Zhang J, Liu H, et al. Efficacy and safety of the Chinese herbal medicine Xiao-qing-long-tang for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol, 2022, 297: 115169.
12.	何強, 梅杰, 錢衛慶, 等. 補腎活血中藥治療肝腎虧虛型膝骨關節炎有效性的系統評價. 中醫臨床研究, 2020, 12(27): 44-49.
13.	尹玫, 李思琦, 王洋, 等. 中藥干預痰證動物模型系統評價研究. 亞太傳統醫藥, 2019, 15(10): 154-157.
14.	Fan X, Su Z, Nie S, et al. Efficacy and safety of Chinese herbal medicine Long Dan Xie Gan Tang in insomnia: a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(11): e19410.
15.	Jin YX, Wu P, Mao YF, et al. Chinese herbal medicine for osteoporosis: a meta-analysis of randomized controlled trials. J Clin Densitom, 2017, 20(4): 516-525.
16.	崔晗, 遲慧彥, 佘遠遙, 等. 中藥養血潤燥法治療特應性皮炎的Meta分析. 世界中西醫結合雜志, 2023, 18(2): 249-255.
17.	Cui J, Lin W, May BH, et al. Chinese herbal therapy in the management of rhinosinusitis-a systematic review and meta-analysis. PLoS One, 2022, 17(12): e0278492.
18.	代欣玥, 訾明杰, 楊巧寧, 等. 基于文獻的中醫藥臨床研究結局指標現狀分析及思考. 中醫雜志, 2022, 63(12): 1122-1127.
19.	Su CX, Yan LJ, Lewith G, et al. Chinese herbal medicine for idiopathic sudden sensorineural hearing loss: a systematic review of randomised clinical trials. Clin Otolaryngol, 2013, 38(6): 455-473.
20.	Ren X, Shi Y, Li G. Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19: a protocol for a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(48): e23261.
21.	王秉權, 申琪. 小青龍湯治療變應性鼻炎Meta分析. 中醫學報, 2015, 30(5): 665-667.
22.	Wong AR, Yang AWH, Li K, et al. Chinese herbal medicine for weight management: a systematic review and meta-analyses of randomised controlled trials. J Obes, 2021, 2021: 3250723.
23.	Jin X, Ruiz Beguerie J, Sze DM, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev, 2016, (4): CD007731.
24.	Luo H, Lü M, Pei X, et al. Chinese herbal medicine for subacute thyroiditis: a systematic review of randomized controlled trials. J Tradit Chin Med, 2014, 34(3): 243-253.
25.	Yang CS, Lin YZ, Guo Q, et al. Chinese herbal medicine xingnaojing injection for hypoxic ischemic encephalopathy in newborns: a systematic review and meta-analysis. Chin J Integr Med, 2018, 24(2): 147-155.
26.	Chen H, Shen Z, Chen J, et al. Chinese herbal medicine for aspirin resistance: a systematic review and meta-analysis. PLoS One, 2016, 11(5): e0154897.
27.	Yang XY, Wang LQ, Li JG, et al. Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med, 2018, 36: 82-89.
28.	Lin Z, Zheng J, Chen M, et al. The efficacy and safety of Chinese herbal medicine in the treatment of knee osteoarthritis: an updated systematic review and meta-analysis of 56 randomized controlled trials. Oxid Med Cell Longev, 2022, 2022: 6887988.
29.	Li H, Kreiner JM, Wong AR, et al. Oral application of Chinese herbal medicine for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. Phytother Res, 2021, 35(6): 3113-3129.
30.	Pang B, Ni Q, Lin YQ, et al. Traditional Chinese patent medicine for treating impaired glucose tolerance: a systematic review and meta-analysis of randomized controlled trials. J Altern Complement Med, 2018, 24(7): 634-655.
31.	Lv J, Liu S, Guo S, et al. Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Ethnopharmacol, 2022, 289: 115033.
32.	Luo Q, Zhang CS, Yang L, et al. Potential effectiveness of Chinese herbal medicine Yu ping feng san for adult allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Altern Med, 2017, 17(1): 485.
33.	Ma LX, Ai P, Li H, et al. The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials. Support Care Cancer, 2015, 23(2): 561-579.
34.	Zhang L, Yang L, Shergis J, et al. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2019, 9(4): e025653.
35.	Ho VW, Tan HY, Guo W, et al. Efficacy and safety of chinese herbal medicine on treatment of breast cancer: a meta-analysis of randomized controlled trials. Am J Chin Med, 2021, 49(7): 1557-1575.
36.	Wang Y, Shi YH, Xu Z, et al. Efficacy and safety of Chinese herbal medicine for depression: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res, 2019, 117: 74-91.
37.	Lu Z, Liu W, Gao H, et al. Traditional Chinese medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLoS One, 2021, 16(5): e0251131.
38.	馬林沁, 張京春, 劉玥, 等. 中藥人參制劑對胰島素抵抗干預效應的Meta分析. 中國循證醫學雜志, 2016, 16(7): 819-827.
39.	李廷謙, 劉雪梅, 張鳴明, 等. 中文期刊發表的中醫藥系統評價/Meta分析現狀調查. 中國循證醫學雜志, 2007, 7(3): 180-188.
40.	Rainkie DC, Abedini ZS, Abdelkader NN. Reporting and methodological quality of systematic reviews and meta-analysis with protocols in diabetes mellitus type Ⅱ: a systematic review. PLoS One, 2020, 15(12): e0243091.

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312(7023): 71-72.
2. Lin SS, Liu CX, Zhang JH, et al. Efficacy and safety of oral Chinese patent medicine combined with conventional therapy for heart failure: an overview of systematic reviews. Evid Based Complement Alternat Med, 2020, 2020: 8620186.
3. Egger M, Davey Smith G, Altman DG, et al. Systematic reviews in health care: meta-analysis in context (2nd editon). London: BMJ Books, 2001.
4. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet, 1999, 354(9193): 1896-1900.
5. Lee AW. Use of network meta-analysis in systematic reviews: a survey of authors. Syst Rev, 2016, 5: 8.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 2009, 339: b2700.
7. 衷敬柏, 王階, 王永炎. 方劑的復雜性與中藥新藥開發. 中國中藥雜志, 2002, 27(5): 321-323.
8. 張素珍. 西藥與中成藥的聯系與區別. 幸福家庭, 2020, (17): 118.
9. 劉洋. 近代中醫體制化歷程(1919-1937). 太原: 山西大學, 2017.
10. Zhang X, Tan R, Lam WC, et al. PRISMA (preferred reporting items for systematic reviews and meta-analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020). Am J Chin Med, 2020, 48(6): 1279-1313.
11. Yan Y, Zhang J, Liu H, et al. Efficacy and safety of the Chinese herbal medicine Xiao-qing-long-tang for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol, 2022, 297: 115169.
12. 何強, 梅杰, 錢衛慶, 等. 補腎活血中藥治療肝腎虧虛型膝骨關節炎有效性的系統評價. 中醫臨床研究, 2020, 12(27): 44-49.
13. 尹玫, 李思琦, 王洋, 等. 中藥干預痰證動物模型系統評價研究. 亞太傳統醫藥, 2019, 15(10): 154-157.
14. Fan X, Su Z, Nie S, et al. Efficacy and safety of Chinese herbal medicine Long Dan Xie Gan Tang in insomnia: a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(11): e19410.
15. Jin YX, Wu P, Mao YF, et al. Chinese herbal medicine for osteoporosis: a meta-analysis of randomized controlled trials. J Clin Densitom, 2017, 20(4): 516-525.
16. 崔晗, 遲慧彥, 佘遠遙, 等. 中藥養血潤燥法治療特應性皮炎的Meta分析. 世界中西醫結合雜志, 2023, 18(2): 249-255.
17. Cui J, Lin W, May BH, et al. Chinese herbal therapy in the management of rhinosinusitis-a systematic review and meta-analysis. PLoS One, 2022, 17(12): e0278492.
18. 代欣玥, 訾明杰, 楊巧寧, 等. 基于文獻的中醫藥臨床研究結局指標現狀分析及思考. 中醫雜志, 2022, 63(12): 1122-1127.
19. Su CX, Yan LJ, Lewith G, et al. Chinese herbal medicine for idiopathic sudden sensorineural hearing loss: a systematic review of randomised clinical trials. Clin Otolaryngol, 2013, 38(6): 455-473.
20. Ren X, Shi Y, Li G. Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19: a protocol for a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(48): e23261.
21. 王秉權, 申琪. 小青龍湯治療變應性鼻炎Meta分析. 中醫學報, 2015, 30(5): 665-667.
22. Wong AR, Yang AWH, Li K, et al. Chinese herbal medicine for weight management: a systematic review and meta-analyses of randomised controlled trials. J Obes, 2021, 2021: 3250723.
23. Jin X, Ruiz Beguerie J, Sze DM, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev, 2016, (4): CD007731.
24. Luo H, Lü M, Pei X, et al. Chinese herbal medicine for subacute thyroiditis: a systematic review of randomized controlled trials. J Tradit Chin Med, 2014, 34(3): 243-253.
25. Yang CS, Lin YZ, Guo Q, et al. Chinese herbal medicine xingnaojing injection for hypoxic ischemic encephalopathy in newborns: a systematic review and meta-analysis. Chin J Integr Med, 2018, 24(2): 147-155.
26. Chen H, Shen Z, Chen J, et al. Chinese herbal medicine for aspirin resistance: a systematic review and meta-analysis. PLoS One, 2016, 11(5): e0154897.
27. Yang XY, Wang LQ, Li JG, et al. Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med, 2018, 36: 82-89.
28. Lin Z, Zheng J, Chen M, et al. The efficacy and safety of Chinese herbal medicine in the treatment of knee osteoarthritis: an updated systematic review and meta-analysis of 56 randomized controlled trials. Oxid Med Cell Longev, 2022, 2022: 6887988.
29. Li H, Kreiner JM, Wong AR, et al. Oral application of Chinese herbal medicine for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. Phytother Res, 2021, 35(6): 3113-3129.
30. Pang B, Ni Q, Lin YQ, et al. Traditional Chinese patent medicine for treating impaired glucose tolerance: a systematic review and meta-analysis of randomized controlled trials. J Altern Complement Med, 2018, 24(7): 634-655.
31. Lv J, Liu S, Guo S, et al. Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Ethnopharmacol, 2022, 289: 115033.
32. Luo Q, Zhang CS, Yang L, et al. Potential effectiveness of Chinese herbal medicine Yu ping feng san for adult allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Altern Med, 2017, 17(1): 485.
33. Ma LX, Ai P, Li H, et al. The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials. Support Care Cancer, 2015, 23(2): 561-579.
34. Zhang L, Yang L, Shergis J, et al. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2019, 9(4): e025653.
35. Ho VW, Tan HY, Guo W, et al. Efficacy and safety of chinese herbal medicine on treatment of breast cancer: a meta-analysis of randomized controlled trials. Am J Chin Med, 2021, 49(7): 1557-1575.
36. Wang Y, Shi YH, Xu Z, et al. Efficacy and safety of Chinese herbal medicine for depression: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res, 2019, 117: 74-91.
37. Lu Z, Liu W, Gao H, et al. Traditional Chinese medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLoS One, 2021, 16(5): e0251131.
38. 馬林沁, 張京春, 劉玥, 等. 中藥人參制劑對胰島素抵抗干預效應的Meta分析. 中國循證醫學雜志, 2016, 16(7): 819-827.
39. 李廷謙, 劉雪梅, 張鳴明, 等. 中文期刊發表的中醫藥系統評價/Meta分析現狀調查. 中國循證醫學雜志, 2007, 7(3): 180-188.
40. Rainkie DC, Abedini ZS, Abdelkader NN. Reporting and methodological quality of systematic reviews and meta-analysis with protocols in diabetes mellitus type Ⅱ: a systematic review. PLoS One, 2020, 15(12): e0243091.

Chinese Journal of Evidence-Based Medicine

Interpretation of the PRISMA extension for Chinese herbal medicine review (PRISMA-CHM)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content